CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
26.31
-0.38 (-1.42%)
At close: Aug 1, 2025, 4:00 PM
26.51
+0.20 (0.76%)
After-hours: Aug 1, 2025, 4:33 PM EDT

Exscientia Statistics

Total Valuation

CG Oncology has a market cap or net worth of $2.01 billion. The enterprise value is $1.32 billion.

Market Cap2.01B
Enterprise Value 1.32B

Important Dates

The next estimated earnings date is Friday, August 15, 2025, before market open.

Earnings Date Aug 15, 2025
Ex-Dividend Date n/a

Share Statistics

CG Oncology has 76.23 million shares outstanding. The number of shares has increased by 1,511.14% in one year.

Current Share Class 76.23M
Shares Outstanding 76.23M
Shares Change (YoY) +1,511.14%
Shares Change (QoQ) +10.33%
Owned by Insiders (%) 0.68%
Owned by Institutions (%) 90.27%
Float 61.13M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 3,029.44
Forward PS n/a
PB Ratio 2.85
P/TBV Ratio 2.85
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 1,991.07
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 30.97, with a Debt / Equity ratio of 0.00.

Current Ratio 30.97
Quick Ratio 30.42
Debt / Equity 0.00
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -16.57% and return on invested capital (ROIC) is -13.18%.

Return on Equity (ROE) -16.57%
Return on Assets (ROA) -12.85%
Return on Invested Capital (ROIC) -13.18%
Return on Capital Employed (ROCE) -19.05%
Revenue Per Employee $5,858
Profits Per Employee -$934,133
Employee Count113
Asset Turnover 0.00
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -21.11% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change -21.11%
50-Day Moving Average 26.28
200-Day Moving Average 28.29
Relative Strength Index (RSI) 49.91
Average Volume (20 Days) 1,018,619

Short Selling Information

The latest short interest is 10.78 million, so 14.15% of the outstanding shares have been sold short.

Short Interest 10.78M
Short Previous Month 11.29M
Short % of Shares Out 14.15%
Short % of Float 17.64%
Short Ratio (days to cover) 12.77

Income Statement

In the last 12 months, CG Oncology had revenue of $662,000 and -$105.56 million in losses. Loss per share was -$1.51.

Revenue662,000
Gross Profit -91.70M
Operating Income -134.40M
Pretax Income n/a
Net Income -105.56M
EBITDA -134.35M
EBIT -134.40M
Loss Per Share -$1.51
Full Income Statement

Balance Sheet

The company has $688.43 million in cash and $1.04 million in debt, giving a net cash position of $687.40 million or $9.02 per share.

Cash & Cash Equivalents 688.43M
Total Debt 1.04M
Net Cash 687.40M
Net Cash Per Share $9.02
Equity (Book Value) 704.76M
Book Value Per Share 9.25
Working Capital 678.55M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$81.98 million and capital expenditures -$238,000, giving a free cash flow of -$82.22 million.

Operating Cash Flow -81.98M
Capital Expenditures -238,000
Free Cash Flow -82.22M
FCF Per Share -$1.08
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin -20,302.27%
Pretax Margin -15,945.17%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

CG Oncology does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -1,511.14%
Shareholder Yield n/a
Earnings Yield -5.26%
FCF Yield -4.10%

Analyst Forecast

The average price target for CG Oncology is $63.30, which is 140.59% higher than the current price. The consensus rating is "Strong Buy".

Price Target $63.30
Price Target Difference 140.59%
Analyst Consensus Strong Buy
Analyst Count 11
Revenue Growth Forecast (5Y) 271.50%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

CG Oncology has an Altman Z-Score of 58.65 and a Piotroski F-Score of 4.

Altman Z-Score 58.65
Piotroski F-Score 4